<DOC>
	<DOCNO>NCT01356615</DOCNO>
	<brief_summary>Low-molecular weight heparin ( LMWHs ) well Unfractionated heparin ( UFH ) use anticoagulation hemodialysis ( HD ) therapy . In study investigator compare clinical efficacy safety LMWH UFH , effect lipid profile .</brief_summary>
	<brief_title>Low Molecular Weight Heparin Hemodialysis Anticoagulation</brief_title>
	<detailed_description>In prospective , randomize , cross-over study investigator compare safety , clinical efficacy Clexane ( enoxaparin sodium ; Sanofi-Aventis ) unfractionated heparin 27 chronic HD patient . Group A receive Clexane ( enoxaparin sodium ; Sanofi-Aventis ) follow 3 month cross Unfractionated heparin 3-month period . Group B receive Unfractionated heparin first cross Clexane , follow 3 month . Heparin anticoagulation , clinical clotting hemorrhage evaluate visual inspection blood drain air trap .</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<mesh_term>Dalteparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<mesh_term>Enoxaparin</mesh_term>
	<criteria>patient end stage renal failure require maintenance dialysis recruit study Patients know bleed disorder Subjects receive oral form anticoagulant therapy ( e.g . warfarin , aspirin ) drug could affect heparin activity ( e.g . digitalis , tetracycline , antihistamine ) also exclude . Subjects continue usual medication ( include lipidlowering therapy ) treat normal manner care physician study .</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>76 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>anticoagulation</keyword>
	<keyword>hemodialysis</keyword>
	<keyword>heparin</keyword>
	<keyword>lipid</keyword>
	<keyword>low molecular weight heparin</keyword>
</DOC>